Accessibility settings

This paper is in the following e-collection/theme issue:

Longitudinal and Cohort Studies in Public Health (892) Gastroenterology and Hepatology (197)

Published on in Vol 9 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/45050, first published .
Hands cradling a paper kidney, symbolizing kidney health and care.

The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study

The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study

Authors of this article:

Suosu Wei1 Author Orcid Image ;   Jian Song2 Author Orcid Image ;   Yujie Xie3 Author Orcid Image ;   Junzhang Huang4 Author Orcid Image ;   Jianrong Yang5 Author Orcid Image
Article Authors Cited by (12) Tweetations (2) Metrics

Journals

  1. Li Y, Wu S, Gao J, Zhang Y, Zuo Y, Tian X, Chen S, Xing A, Wang A, He Y. Association of Stroke With Metabolic Dysfunction–Associated Fatty Liver Disease With and Without CKD. American Journal of Kidney Diseases 2024;83(4):477 View
  2. Nardolillo M, Rescigno F, Bartiromo M, Piatto D, Guarino S, Marzuillo P, Miraglia del Giudice E, Di Sessa A. Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective. World Journal of Gastroenterology 2024;30(15):2081 View
  3. Yang D, Ma L, Cheng Y, Shi H, Liu Y, Shi C. Utility of Anthropometric Indexes for Detecting Metabolic Syndrome in Resource-Limited Regions of Northwestern China: Cross-Sectional Study. JMIR Public Health and Surveillance 2024;10:e57799 View
  4. Liu W, Sun X. Does metabolic dysfunction-associated fatty liver disease increase the risk of chronic kidney disease? A meta-analysis of cohort studies. BMC Nephrology 2024;25(1) View
  5. Katsiki N, Kolovou G, Vrablik M. Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease. Current Cardiology Reports 2025;27(1) View
  6. Zisis M, Chondrogianni M, Androutsakos T, Rantos I, Oikonomou E, Chatzigeorgiou A, Kassi E. Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment. Biomolecules 2025;15(3):324 View
  7. Bazmi S, Fardaei M, Homayounfar R, Kazemi M, Pezeshki B, Malekzadeh R, Ghahramani N, Farjam M. Cross-sectional and longitudinal associations between fatty liver index and kidney function using updated MASLD and CKD–EPI 2021 definitions: a population-based study with region-specific cutoffs. European Journal of Medical Research 2025;31(1) View
  8. Ji X, Jiang J, Liu Y, Li L, Yang H, Ma Z, Wang C, Zhang T, Zhao Y, Liu Y, Xia Y. The association between steatotic liver disease and chronic kidney disease: a meta-analysis and Mendelian randomization study highlighting metabolic comorbidities. Nutrition & Diabetes 2026;16(1) View
  9. Salcedo Joven I, Fernández Ramos A, Cinza Sanjurjo S. Estudio de la asociación entre la enfermedad hepática metabólica y el deterioro de la función renal: Una revisión sistemática actualizada y metaanálisis de estudios prospectivos (2020–2025). Medicina de Familia. SEMERGEN 2026;52(5):102779 View
  10. Soares A, Loli D, Carvalho G, Delfino V, Bignardi P. Association between metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease and chronic kidney disease: a systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders 2026 View
  11. Azoz N, Shehata M, Abbas W, Gadelkareem R, Abdel Aziz E. Is the metabolic dysfunction-associated steatotic liver disease a predictor of chronic kidney disease?. World Journal of Nephrology 2026;15(2) View
  12. Rapeti A, Pilla R, Chouthai G, Thota A, Shashidhar M, Vanamada C. Renal Dysfunction Across Etiologies of Chronic Liver Disease: A Cross-Sectional Study From a Tertiary Care Center. Cureus 2026 View